LiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2A1xs23
via IFTTT